Literature DB >> 25475188

[Aniridia syndrome: clinical findings, problematic courses and suggestions for optimization of care ("aniridia guide")].

B Käsmann-Kellner1, B Seitz.   

Abstract

BACKGROUND: Congenital aniridia manifests in different forms: it can be transmitted in an autosomal dominant way, as sporadic aniridia and as part of several syndromes including WAGR (Wilms tumor, aniridia, genitourinary abnormalities and intellectual disability) and WAGRO syndromes (WAGR and obesity). Furthermore, recent research shows that aniridia associated with alterations in the PAX6 gene often shows further systemic implications (e.g. endocrine, metabolic and neurological pathologies). Therefore, PAX6-related aniridia is more and more considered to be and described as aniridia syndrome or PAX6 syndrome.
PURPOSE: We present a group of 130 patients with congenital aniridia to enhance awareness of the complexity of the disease. Different to other congenital visual impairments aniridia is characterized by many ocular complications arising during the lifetime which may lead to total blindness (e.g. cataract, aniridic keratopathy and secondary glaucoma). Furthermore, there is a specific surgical risk entity: aniridia fibrosis syndrome and anterior segment fibrosis syndrome (ASFS) which lead to a non-infectious fibrous scarring and membrane formation of the anterior segment, often followed by hypotonia and phthisis. Aniridic glaucoma presents yet another severe complication which is often diagnosed late due to diagnostic problems and which may lead to irreversible optic nerve damage. DISCUSSION: The following approaches might help to improve the lifelong care of aniridia patients and might benefit the aim to lessen the impact of complications in aniridia: topical prophylaxis of aniridic corneal epitheliopathy from a very early age, regular measurement of intraocular pressure starting in young children, annual visual evoked potential (VEP) measurements and routine visual field testing as soon as possible, comprehensive optimization of surgical care independent of department location (only the very best surgeons within their subspecialty should treat the different complications) while one experienced pediatric and low vision ophthalmologist should follow the patient continuously ("aniridia guide" for the patient), thus monitoring the disease and stages of complications and advising the patient where to go for surgical treatment. This low vision ophthalmologist continuously follows the patient's course including adaptation of low vision aids according to the course of the disease, helping the patient concerning integration at school and at the place of work and advising about social and legal compensation possibilities. In addition, the guiding ophthalmologist should inform patients with aniridia about possible systemic manifestations of PAX6 syndrome concerning metabolic and neurological implications and should initiate appropriate investigations when applicable.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25475188     DOI: 10.1007/s00347-014-3060-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  30 in total

1.  Non-invasive anterior segment and posterior segment optical coherence tomography and phenotypic characterization of aniridia.

Authors:  Kevin Gregory-Evans; Richard Cheong-Leen; Sheena M George; Judy Xie; Mariya Moosajee; Patricio Colapinto; Cheryl Y Gregory-Evans
Journal:  Can J Ophthalmol       Date:  2011-07-07       Impact factor: 1.882

Review 2.  Ocular coloboma: a reassessment in the age of molecular neuroscience.

Authors:  C Y Gregory-Evans; M J Williams; S Halford; K Gregory-Evans
Journal:  J Med Genet       Date:  2004-12       Impact factor: 6.318

3.  Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects.

Authors:  Cheryl Y Gregory-Evans; Xia Wang; Kishor M Wasan; Jinying Zhao; Andrew L Metcalfe; Kevin Gregory-Evans
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

4.  Ocular and systemic findings in a survey of aniridia subjects.

Authors:  Peter A Netland; Michele L Scott; John W Boyle; James D Lauderdale
Journal:  J AAPOS       Date:  2011-12       Impact factor: 1.220

5.  Microphthalmia, late onset keratitis, and iris coloboma/aniridia in a family with a novel PAX6 mutation.

Authors:  Xueshan Xiao; Shiqiang Li; Qingjiong Zhang
Journal:  Ophthalmic Genet       Date:  2011-12-15       Impact factor: 1.803

6.  Inherited PAX6, NF1 and OTX2 mutations in a child with microphthalmia and aniridia.

Authors:  R Alex Henderson; Kathy Williamson; Sally Cumming; Michael P Clarke; Sally Ann Lynch; Isabel M Hanson; David R FitzPatrick; Sanjay Sisodiya; Veronica van Heyningen
Journal:  Eur J Hum Genet       Date:  2007-04-04       Impact factor: 4.246

7.  Asymmetric phenotype of Axenfeld-Rieger anomaly and aniridia associated with a novel PITX2 mutation.

Authors:  Simon K Law; Maha Sami; Natik Piri; Anne L Coleman; Joseph Caprioli
Journal:  Mol Vis       Date:  2011-05-06       Impact factor: 2.367

8.  Recurrent progressive anterior segment fibrosis syndrome following a descemet-stripping endothelial keratoplasty in an infant with congenital aniridia.

Authors:  Mihir Kothari; Kavita Rao; Samita Moolani
Journal:  Indian J Ophthalmol       Date:  2014-02       Impact factor: 1.848

9.  Raised risk of Wilms tumour in patients with aniridia and submicroscopic WT1 deletion.

Authors:  Veronica van Heyningen; Jan M N Hoovers; Jan de Kraker; John A Crolla
Journal:  J Med Genet       Date:  2007-07-14       Impact factor: 6.318

10.  PAX6 mutation in association with ptosis, cataract, iris hypoplasia, corneal opacification and diabetes: a new variant of familial aniridia?

Authors:  Neena M Peter; Martin Leyland; Hardeep S Mudhar; Jo Lowndes; Katharine R Owen; Helen Stewart
Journal:  Clin Exp Ophthalmol       Date:  2013-05-03       Impact factor: 4.207

View more
  4 in total

1.  Congenital Aniridia with Ectopia Lentis.

Authors:  Rakhi Kusumesh; Anita Ambastha
Journal:  J Clin Diagn Res       Date:  2016-07-01

2.  Preferentially Paternal Origin of De Novo 11p13 Chromosome Deletions Revealed in Patients with Congenital Aniridia and WAGR Syndrome.

Authors:  Tatyana A Vasilyeva; Andrey V Marakhonov; Natella V Sukhanova; Sergey I Kutsev; Rena A Zinchenko
Journal:  Genes (Basel)       Date:  2020-07-17       Impact factor: 4.096

3.  A sporadic case of congenital aniridia caused by pericentric inversion inv(11)(p13q14) associated with a 977 kb deletion in the 11p13 region.

Authors:  Tatyana A Vasilyeva; Andrey V Marakhonov; Marina E Minzhenkova; Zhanna G Markova; Nika V Petrova; Natella V Sukhanova; Philipp A Koshkin; Denis V Pyankov; Ilya V Kanivets; Sergey A Korostelev; Irina A Krynskaya; Nadezhda V Shilova; Sergey I Kutsev; Vitaly V Kadyshev; Rena A Zinchenko
Journal:  BMC Med Genomics       Date:  2020-09-18       Impact factor: 3.063

4.  Construction of ceRNA network and identification of hub genes in aniridia-associated keratopathy using bioinformatics analysis.

Authors:  Jiawen Wu; Daowei Zhang; Jihong Wu; Shenghai Zhang
Journal:  Front Genet       Date:  2022-09-23       Impact factor: 4.772

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.